Nkarta Inc

Nkarta, Inc. reported a second-quarter net loss of $40.37 million, or $0.54 per share, wider than the $22.98 million loss, or $0.31 per share, in the prior-year quarter. The wider loss was driven by higher research and development expenses of $29.05 million and a surge in general and administrative expenditure to $14.08 million from $6.41 million. As of June 30, 2026, cash, cash equivalents, restricted cash, and investments totaled $243.18 million, which the company expects to fund operations through 2029. On the clinical front, following FDA discussion on outpatient dosing, Nkarta continues enrolling patients in the Phase 1/2 Ntrust-1 and Ntrust-2 trials of its lead candidate NKX019 across multiple autoimmune diseases, with patients receiving 4 billion cells per dose across three doses for a total of 12 billion cells; initial clinical data from both trials is expected to be presented at a medical conference in 2026.